NCT06968910 (Urol-CBD) is a NA clinical trial of CANNEFF® SUP rectal suppositories in Prostatitis, sponsored by Palacky University.

Who is sponsoring NCT06968910?

NCT06968910 is sponsored by Palacky University.

What drugs are being tested in NCT06968910?

Interventions in NCT06968910: CANNEFF® SUP rectal suppositories.

What condition does NCT06968910 study?

NCT06968910 studies Prostatitis.

Is NCT06968910 still recruiting?

NCT06968910 is currently completed. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT06968910: Urol-CBD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CBD-based Therapy to Attenuate Non-bacterial Prostatitis Symptoms

Completed NA Last updated 13 May 2025

What this trial tests

NA trial testing CANNEFF® SUP rectal suppositories in Prostatitis in 35 participants. Completed in 1 January 2025.

Timeline

1 December 2022

Primary endpoint
1 April 2024

1 January 2025

Quick facts

Lead sponsor	Palacky University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	35
Start date	1 December 2022
Primary completion	1 April 2024
Estimated completion	1 January 2025
Sites	1 location across Czechia

Drugs / interventions tested

CANNEFF® SUP rectal suppositories

Conditions studied

Prostatitis — all drugs for Prostatitis →

Sponsor

Palacky University

Who can join

Adults 18 to 50, male only, with Prostatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy and safety of the medical device rectal CANNEFF® SUP suppositories containing two active ingredients cannabidiol (CBD) and hyaluronic acid (HA) in alleviating non-bacterial prostatitis symptoms and improving quality of life in men will be evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways.
Dubnika A, Jurgelane I, Grava-Ceplite A, Tornaci S, et al · · 2026 · cited 1× · PMID 42039297 · DOI 10.1016/j.apsb.2025.10.001

Verify or expand the search:

Other Palacky University trials

Trials by the same sponsor.

NCT07321483 — Reflex Therapy of Temporomandibular Dysfunctions · NA · recruiting
NCT07135934 — Effects of Single Sodium Bicarbonate Supplementation on National-Level Finswimming Performance · NA · recruiting
NCT06518460 — Functional Efficiency of Self-sufficiency Test · completed
NCT06406764 — Effects of a Plyometric Training Program on Youths With Different Biological Maturity in Sport · NA · completed
NCT05982665 — Effect of Inhaled Molecular Hydrogen on Recovery Process After Downhill Walking on the Treadmill · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06968910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Palacky University
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06968910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing